SCHEMBL23328987

SCHEMBL23328987

Cc1c(-c2ccc(C(C)C)cc2)nnn1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
TP53 P04637 3/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
RAB9A P51151 3/20 0.39
NOTUM Q6P988 3/20 0.39
NPC1 O15118 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
ERBB2 P04626 1/20 0.38
MAPT P10636 3/20 0.38
KDM4E B2RXH2 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25045153 0.78 NPC1 (0.45) RAB9ANPC1ALDH1A1
SCHEMBL12523116 0.77 NPC1 (0.47) RAB9ANPC1MAPTSMN1; SMN2POLB
SCHEMBL15290222 0.73 SMN1; SMN2 (0.53) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL31617510 0.72 TMEM97 (0.40) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL10176300 0.71 HTR7 (0.43) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL24120001 0.70 TMEM97 (0.40) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL23329066 0.68 TMEM97 (0.44) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL15341756 0.68 CYP11B2 (0.58) LMNARAB9ATMEM97SIGMAR1MAPT
SCHEMBL23328881 0.67 NOTUM (0.44) LMNATP53USP2CYP1A2CYP2C9
SCHEMBL197335 0.66 KIF11 (0.52) LMNATP53USP2CYP2C9RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO LMNA 4767/4885TP53 3342/4885USP2 823/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO LMNA 4767/4885TP53 3342/4885USP2 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.